Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Senior Appointment

30 Jan 2008 07:01

ViaLogy PLC30 January 2008 VIALOGY PLC APPOINTS HEAD OF OPERATIONS AND ENGINEERING London, January 30, 2008 - ViaLogy PLC (AIM: VIY), a leading innovator ofnetwork-centric real time signal processing platforms for integrated security,safety, operations management and business continuity applications, todayannounces the appointment of Hugo Fruehauf as Chief Operating Officer (COO) andVice President of Engineering at its wholly-owned American subsidiary company,ViaLogy LLC ('ViaLogy'), of Pasadena, California. This senior appointment strengthens the company's engineering and productioncapabilities and advances efforts to establish its unique product offerings -Sensor Policy Manager (SPM), MicroSPM and MPEX Electronic Eye - in high demandcommercial markets. Fruehauf joins ViaLogy from Frequency Electronics Inc. (FEI), a leadingmanufacturer of precision frequency sources and frequency/time systems forsatellites, missiles, aircraft and a host of ground platforms, where he was VicePresident and Chief Technology Officer (CTO). Hugo has also held President/CEOand CTO positions at subsidiaries of FEI, the Defense Group of AlliantTechsystems, Datum Inc., and Ball-Efratom (a Ball Aerospace company); companiesserving both commercial and military/governmental system markets. Prior tothese roles, while at Rockwell International, he was the Chief Engineer for thedesign and development of the satellite for the now famous GPS GlobalPositioning System. He also played a leading role in the Apollo moon landingprogram, as Chief Test Conductor and Complex Operations Manager for the secondstage of the Saturn V launch vehicle. Mr. Fruehauf is considered a leading expert in GPS navigation, positioning andprecision timing for commercial and military applications, as well as precisionfrequency sources and network cryptographic security technologies. He is also anAdjunct Professor at Pepperdine University. Commenting on his appointment Hugo Fruehauf said: "I'm looking forward to leading an incredibly competent team at the Pasadenafacility and hopefully contribute to innovation, a systems engineering focus,and the operational glue that will bring ViaLogy to its full potential." Welcoming Hugo to ViaLogy, Dr. Robert W. Dean, President/CEO, said: "We are delighted that Hugo is joining the team at ViaLogy. He brings a wealthof experience in product design and development that will be vital as weroll-out our products to the market. We are all looking forward to an excitingyear ahead." Mr. Fruehauf is a Registered Professional Engineer in Control Systems (State ofCalifornia); an Executive MBA graduate (Pepperdine University); an ElectronicEngineering Technology graduate (DeVry University); the compiler of a "PrecisionTime and Frequency Handbook" and a religious book "God Without Dogma"; author ofmany technical papers on atomic oscillators, telecommunications, networkcryptography, and GPS technologies; holds numerous patents; and received awardsfor his role in the Apollo program, GPS, and an IEEE technical paper. ViaLogyRobert W Dean, President/CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 Nominated Advisor (Seymour Pierce)Mark Percy +44 (0) 20-7107-8000 PR Consultants - Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0) 20-7822-0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications and sensor fusion. ViaLogy is currentlydeploying and designing computational systems, powered by its patentedtechnologies, for applications in life sciences, public safety and security,surveillance, defense and geoseismology. Vialogy focuses on market drivenproblems where automation, timeliness, quality and reliability of informationprocessing are essential. ViaLogy's core competency incorporates rapidly andaccurately detecting weak signals buried in high noise background and clutter.This technology can be employed to solve problems involving sensor integrationand information overload challenges involving video, telephony and controlsensors, as well as for enhancement of numerous signal processing applications.For more information, visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.